Literature DB >> 8801453

Esophagitis and alendronate.

U I Liberman, L J Hirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8801453     DOI： 10.1056/NEJM199610033351416

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

Authors:  Ronald Emkey
Journal:  MedGenMed       Date:  2004-07-19

Review 2.  Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

Authors:  D Jaspersen
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 3.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

Review 4.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 5.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

6.  Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.

Authors:  Yeesuk Kim; Yuxi Tian; Jianxiao Yang; Vojtech Huser; Peng Jin; Christophe G Lambert; Hojun Park; Seng Chan You; Rae Woong Park; Peter R Rijnbeek; Mui Van Zandt; Christian Reich; Rohit Vashisht; Yonghui Wu; Jon Duke; George Hripcsak; David Madigan; Nigam H Shah; Patrick B Ryan; Martijn J Schuemie; Marc A Suchard
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.